Project Grant H25PS004315

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $243,361 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Rush University Medical Center in Chicago, Illinois. The grant funding will be used to establish workflows for rapid and inexpensive whole genome sequencing (WGS) of Neisseria gonorrhoeae (N. gonorrhoeae) directly from urine, throat, and rectal specimens collected as part of clinical care. The project aims to evaluate...

This $195,480 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development and pilot implementation of a low-cost, point-of-care diagnostic assay that can detect Neisseria gonorrhoeae infection and molecular markers of antimicrobial resistance. The goal is to address the limited laboratory infrastructure and high burden of gonorrhea in resource-limited settings, which...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,095,000.00 in funding to Louisiana State University Health Sciences Center-Shreveport to investigate the role of macrophage colonization by the bacteria Neisseria gonorrhoeae (NG) during gonorrhea infection. The key objectives of this 5-year research project are to: (1) identify the host receptors required...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $796,454 to The Johns Hopkins University to develop a rapid antimicrobial susceptibility testing (AST) platform for Neisseria gonorrhoeae (NG). The platform will utilize single-cell mRNA profiling to assess NG susceptibility to multiple antimicrobials within 1 hour, directly from clinical specimens. This will address the critical need...

This $299,999 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a novel bispecific antibody for the prevention of gonorrhea infections. The awardee, Planet Biotechnology Incorporated, is a for-profit biotechnology company focused on engineering innovative immunotherapeutic proteins using plant-based expression systems. The key objectives of this 2-year...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $631,381 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of North Carolina at Chapel Hill (UNC-CH). The grant, awarded on May 14, 2024, will fund research to modulate immune responses mediated by the PorB protein from Neisseria gonorrhoeae. The research aims to understand how PorB suppresses immune responses, with the goal of developing more effective outer...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $233,250 project grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Washington to develop and validate a rapid, point-of-care diagnostic test to detect antibiotic resistance in the bacteria that causes syphilis (Treponema pallidum). The key deliverables include: A multiplexed, point-of-care allele-specific loop-mediated isothermal amplification (AS-LAMP) assay to detect genetic markers of...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA 93.855 Allergy and Infectious Diseases Research, aims to optimize methods for recovering Treponema pallidum genomes from diverse clinical specimens. Specifically, the project will develop a tiling amplicon sequencing approach to improve the analytical sensitivity and scalability of T. pallidum genome recovery, which is currently limited by low DNA levels in most samples and complex...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded Sherlock Biosciences, Inc. a $298,948 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a power-free molecular diagnostic device for detecting sexually transmitted infections (STIs), specifically Chlamydia trachomatis and Neisseria gonorrhoeae, from self-collected vaginal swabs. The project aims to create an accurate, easy-to-use, and inexpensive STI screening product that...

This $175,000 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop a decentralized antimicrobial resistance (AMR) surveillance system for resource-limited settings. The project will assess the detection of drug-resistant bacteria and antimicrobial bacteriophages using cost-effective long-read sequencing on Flongle platforms. This research focuses on monitoring...